Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 6/20 | 0.60 |
| ▸ | ACE | P12821 | 6/20 | 0.60 |
| ▸ | CPA1 | P15085 | 1/20 | 0.60 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.60 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.58 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.53 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.53 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30445690 | 1.00 | MME (0.60) | MMEACECPA1ACE2FOLH1 | |
| SCHEMBL2493049 | 0.94 | ACE (0.65) | MMEACECPA1ACE2FOLH1 | |
| SCHEMBL4073351 | 0.94 | ACE (0.65) | MMEACECPA1ACE2FOLH1 | |
| SCHEMBL2545591 | 0.94 | ACE (0.65) | MMEACECPA1ACE2FOLH1 | |
| SCHEMBL31287928 | 0.94 | ACE (0.65) | MMEACECPA1ACE2FOLH1 | |
| Water SCHEMBL20489335 | 0.93 | ACE (0.64) | MMEACECPA1ACE2FOLH1 | |
| Water SCHEMBL20495306 | 0.93 | ACE (0.64) | MMEACECPA1ACE2FOLH1 | |
| Water SCHEMBL20489337 | 0.93 | ACE (0.64) | MMEACECPA1ACE2FOLH1 | |
| Water SCHEMBL29167823 | 0.93 | ACE (0.64) | MMEACECPA1ACE2FOLH1 | |
| Water SCHEMBL29167817 | 0.93 | ACE (0.64) | MMEACECPA1ACE2FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2007348-B1 | PAEDIATRIC AMINO ACID SOLUTION FOR PARENTERAL NUTRITION | FRESENIUS KABI DE GMBH (DE) | 2014-12-10 | — | — | EP | claimed |
| US-12527851-B2 | Methods and materials for treating cancer | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2026-01-20 | — | — | US | disclosed |
| US-11911455-B2 | HPV therapeutic nucleic acid vaccine | BEIJING AEONVITAL BIOMEDICINE RESEARCH CO., LTD. (CN) | 2024-02-27 | — | — | US | disclosed |
| US-20240009294-A1 | HPV Therapeutic Nucleic Acid Vaccine | BEIJING AEONVITAL BIOMEDICINE RESEARCH CO., LTD. (CN) | 2024-01-11 | — | — | US | disclosed |
| EP-4252852-A2 | METHODS AND MATERIALS FOR TREATING CANCER | Mayo Foundation for Medical Education and Research (US) | 2023-10-04 | — | — | EP | disclosed |
| WO-2023142647-A1 | NEW TYPE THERAPEUTIC NUCLEIC ACID VACCINE FOR HPV | 北京循生生物医学研究有限公司 | 2023-08-03 | — | — | WO | disclosed |
| CN-114134165-B | Novel HPV therapeutic nucleic acid vaccine | 北京循生生物医学研究有限公司 | 2022-04-29 | — | — | CN | disclosed |
| CN-114134165-A | Novel HPV therapeutic nucleic acid vaccine | 北京循生生物医学研究有限公司 | 2022-03-04 | — | — | CN | disclosed |
| US-20110262962-A1 | METHOD FOR PRODUCING PEPTIDES | AJINOMOTO CO., INC. (JP) | 2011-10-27 | — | — | US | disclosed |
| US-20070292916-A1 | MUTANT PROTEIN HAVING THE PEPTIDE-SYNTHESIZING ACTIVITY | AJINOMOTO CO., INC. (JP) | 2007-12-20 | — | — | US | disclosed |
| CN-101087878-A | Mutant protein having the peptide-synthesizing activity | AJINOMOTO KK (JP) | 2007-12-12 | — | — | CN | disclosed |
| EP-1829968-A1 | MUTANT PROTEIN HAVING PEPTIDE-PRODUCTION ACTIVITY | Ajinomoto Co., Inc. (JP) | 2007-09-05 | — | — | EP | disclosed |
| US-20070190602-A1 | Mutant protein having the peptide-synthesizing activity | AJINOMOTO CO., INC (JP) | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12527851-B2 | Methods and materials for treating cancer | APOBEC3A, APOBEC3G, APOBEC3B | MME 2354/4885ACE 3121/4885CPA1 224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.